The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial (Q34984126)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

adrenocortical carcinoma

1 reference

based on heuristic

inferred from title

Antonio M Lerario

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24849545%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

author name string

Francis P Worden

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24849545%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Carole A Ramm

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24849545%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Elizabeth A Hesseltine

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24849545%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Walter M Stadler

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24849545%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Tobias Else

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24849545%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Manisha H Shah

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24849545%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Edem Agamah

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24849545%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Krishna Rao

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24849545%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Gary D Hammer

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24849545%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

publication date

22 May 2014

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Hormones and Cancer

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24849545%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24849545%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24849545%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

232-239

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24849545%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Update in adrenocortical carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4298824

8 July 2018

A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4298824

8 July 2018

A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4298824

8 July 2018

Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4298824

8 July 2018

Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and β-catenin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4298824

8 July 2018

R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4298824

8 July 2018

Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4298824

8 July 2018

The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4298824

8 July 2018

Combination of anti-IGF-1R antibody A12 and ionizing radiation in upper respiratory tract cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4298824

8 July 2018

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4298824

8 July 2018

The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4298824

8 July 2018

Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4298824

8 July 2018

Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4298824

8 July 2018

Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4298824

8 July 2018

Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4298824

8 July 2018

Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4298824

8 July 2018

Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4298824

8 July 2018

Expression of insulin-like growth factor-II and its receptor in pediatric and adult adrenocortical tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4298824

8 July 2018

Adrenal cortical carcinoma--review of current knowledge and treatment practices

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4298824

8 July 2018

Role of the insulin-like growth factor system in adrenocortical growth control and carcinogenesis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4298824

8 July 2018

A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4298824

8 July 2018

Insulin-like growth factor-I receptor (IGF-IR) targeting with monoclonal antibody cixutumumab (IMC-A12) inhibits IGF-I action in endometrial cancer cells.

1 reference

https://api.crossref.org/works/10.1007%2FS12672-014-0182-1

21 January 2018

Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871.

1 reference

https://api.crossref.org/works/10.1007%2FS12672-014-0182-1

21 January 2018

Combination chemotherapy in advanced adrenocortical carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS12672-014-0182-1

21 January 2018

Insulin-like growth factors and cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12672-014-0182-1

21 January 2018

Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group

1 reference

https://api.crossref.org/works/10.1007%2FS12672-014-0182-1

21 January 2018

Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS12672-014-0182-1

21 January 2018

Identifiers

10.1007/S12672-014-0182-1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24849545%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24849545%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24849545%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34984126&oldid=2197111453"